Linzagolix

Linzagolix
Clinical data
Other names	KLH-2109; OBE-2109
Routes of; administration	By mouth[1][2]
Drug class	GnRH modulator; GnRH antagonist; Antigonadotropin
Identifiers
	IUPAC name 3-{5-[(2,3-difluoro-6-methoxyphenyl)methoxy]-2-fluoro-4-methoxyphenyl}-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid;
CAS Number	935283-04-8;
PubChem CID	16656889;
ChemSpider	17590169;
UNII	7CDW97HUEX;
KEGG	D11608;
ChEMBL	ChEMBL3668014;
Chemical and physical data
Formula	C22H15F3N2O7S
Molar mass	508.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(C1=C(C(N2C3=CC(OCC4=C(OC)C=CC(F)=C4F)=C(OC)C=C3F)=O)C(NC2=O)=CS1)O;
	InChI InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30); Key:BMAAMIIYNNPHAB-UHFFFAOYSA-N;

Linzagolix (INN; developmental code names KLH-2109, OBE-2109) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.[1][3][2] As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.[1]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.